The cholesterol test your patients may be missing—and what it reveals that LDL can't

By MDLinx staffFact-checked by Davi ShermanPublished July 8, 2026

Industry Buzz

I think the best use case is when you’re treating somebody with lipid-lowering therapy. Maybe you’ve gotten them to the LDL cholesterol you were trying to get them to and now you want to adjudicate whether they’ve really gotten to the goal that you want them to get.

—Michael Shapiro, MD, via NBC News

Having a very high apoB will pick up more people than just LDL. But then what you do about that is another matter. If you only had apoB, you don't know whether to focus on LDL-lowering or weight loss or glucose control... then you can personalize it.

—Kausik Ray, MD, via Men’s Health

LDL cholesterol has been the cornerstone of cardiovascular risk assessment for decades. But what if the number physicians have relied on for years isn’t the best way to identify who is truly at risk for a heart attack?

A growing body of evidence suggests that apolipoprotein B (apoB), which measures the number of atherogenic lipoprotein particles rather than the amount of cholesterol they carry, may outperform LDL-C as a predictor of atherosclerotic cardiovascular disease (ASCVD).^[]^[]^[]^[]

While LDL-C remains the primary treatment target in current US guidelines, apoB is increasingly being recognized as an important tool for refining cardiovascular risk, particularly when traditional lipid markers tell an incomplete story.^[]^[]^[]^[]

Why particle number matters more than cholesterol content

LDL-C measures how much cholesterol is contained within LDL particles. ApoB, by contrast, measures the number of potentially atherogenic lipoprotein particles.^[]^[]

That distinction matters because two patients can have identical LDL-C levels but very different numbers of circulating particles.^[] Smaller, cholesterol-depleted LDL particles carry less cholesterol individually, meaning LDL-C can appear acceptable while the actual number of particles capable of entering the arterial wall remains high.^[]^[]

In a large modeling study published in JAMA, researchers found that using apoB to guide lipid-lowering therapy would identify more patients who could benefit from treatment and prevent more myocardial infarctions, strokes, and cardiovascular deaths than strategies based on LDL-C or non-HDL cholesterol alone.^[]^[]

The findings add to years of observational data showing that apoB better reflects the total burden of atherogenic particles driving plaque formation.^[]^[]

Which patients benefit most from apoB testing?

The biggest advantage of apoB testing appears when LDL-C and particle number are discordant.

This is particularly common in patients with obesity, metabolic syndrome, diabetes, or elevated triglycerides, where LDL particles often carry less cholesterol than expected.^[]^[] In these patients, LDL-C may underestimate residual CV risk.

“I think the best use case is when you're treating somebody with lipid-lowering therapy,” Michael Shapiro, MD, a preventive cardiologist and the chair of the American Heart Association Council on Lipidology, Lipoprotein, Metabolism and Thrombosis, told NBC News. “Maybe you've gotten them to the LDL cholesterol you were trying to get them to and now you want to adjudicate whether they've really gotten to the goal that you want them to get.”^[]

Population studies have found substantial variability in apoB levels even among individuals without traditional metabolic risk factors, raising questions about whether broader use of apoB could improve risk stratification.^[]

Guidelines are evolving—but LDL still leads

The 2026 AHA/ACC dyslipidemia guidelines acknowledge apoB as a more precise marker of atherogenic particle burden and recommend its use in selected patients as a risk-enhancing factor and secondary treatment target.^[] Even so, LDL-C remains the primary therapeutic target in the US.

“Having a very high apoB will pick up more people than just LDL. But then what you do about that is another matter,” Kausik Ray, MD, a cardiologist at Imperial College London, told WIRED. “If you only had apoB, you don’t know whether to focus on LDL-lowering or weight loss or glucose control ... Then you can personalize it.”^[]

As preventive cardiology continues shifting toward earlier, more individualized risk assessment, apoB may become less of a specialty test and more of a routine part of cardiovascular prevention.

SHARE THIS ARTICLE